O
Ocular Therapeutix is a clinical-stage biopharmaceutical company developing AXPAXLI, a sustained-release intravitreal injection for retinal diseases, now in Phase 3 trials for wet AMD. The hiring mix—skewed toward manufacturing, quality, and marketing alongside engineering—reflects the operational demands of scaling from late-stage development into potential commercialization. Active projects span method validation, technology transfer, clinical production setup, and reimbursement strategy, while documented pain points center on regulatory compliance, drug-delivery complexity, and patient access barriers typical of ophthalmology.
Tech Stack 17 technologies
Core StackSolidWorks Salesforce Active Directory HPLC UPLC GCP LIMS Pro/ENGINEER ADP Workforce Now Veeva CRM FMEA macOS Azure Portal Endpoint Manager Eclipse Adobe Acrobat Veeva Vault
What Ocular Therapeutix, Inc. Is Building
◆Challenges
- Reducing complexity of standard of care
- Maintaining compliance with regulations
- Patient access challenges
- Reimbursement process complexity
- Reducing complexity of drug delivery
- Supporting batch release
- Document archiving and retrieval
- Securing reimbursement for buy-and-bill products
- Market adoption
- Access and reimbursement issues
▲Active Projects
- Method validation
- In-surgery training program
- Retina congress strategy expansion
- Technology transfer and clinical production
- Quarterly rebate communication
- Stability program
- Device testing
- Document archive program
- Documentation control process enhancements
- Quality and process improvement initiatives
Hiring Activity
20 roles · 20 in 30d
Department
Seniority
Notable leadership hires: Environment Health and Safety Director, Retina Marketing Director
Company intelligence